Story perspectives
Roche's Vabysmo Surpasses $4B Sales Despite Q4 Dip
1/30/2025
23 2
1 of 1
Story summary
- Roche's eye medication Vabysmo achieved over $4 billion in sales in its third year, ranking third overall.
- Fourth-quarter sales fell short of analyst expectations by 2%, linked to a recent prefilled syringe launch.
- Vabysmo maintains a strong U.S. market presence for eye conditions, with growth projected for 2025.
- New drugs accounted for 56% of Roche's pharma sales in 2024, with crucial trial results anticipated in 2025.
